Sandbox:kalpana: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 10: Line 10:


==Pathophysiology==
==Pathophysiology==
It is understood that fetal hydantoin syndrome s the result of infants born to mothers with [[seizure]] disorders treated with [[anticonvulsant]] medications during pregnancy are at an increased risk for teratogenic effects.<ref name="pmid23082254">{{cite journal| author=Singh R, Kumar N, Arora S, Bhandari R, Jain A| title=Fetal hydantoin syndrome and its anaesthetic implications: a case report. | journal=Case Rep Anesthesiol | year= 2012 | volume= 2012 | issue=  | pages= 370412 | pmid=23082254 | doi=10.1155/2012/370412 | pmc=3469078 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23082254  }} </ref>
It is understood that fetal hydantoin syndromes is the result of infants born to mothers with [[seizure]] disorders treated with [[anticonvulsant]] medications during pregnancy are at an increased risk for [[teratogenic]] effects.<ref name="pmid23082254">{{cite journal| author=Singh R, Kumar N, Arora S, Bhandari R, Jain A| title=Fetal hydantoin syndrome and its anaesthetic implications: a case report. | journal=Case Rep Anesthesiol | year= 2012 | volume= 2012 | issue=  | pages= 370412 | pmid=23082254 | doi=10.1155/2012/370412 | pmc=3469078 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23082254 }} </ref>Although the exact pathogenesis of [[phenytoin]] (PTN) embryo toxicity is not clear, some possible mechanisms have been proposed.<ref name="pmid16611127">{{cite journal| author=Webster WS, Howe AM, Abela D, Oakes DJ| title=The relationship between cleft lip, maxillary hypoplasia, hypoxia and phenytoin. | journal=Curr Pharm Des | year= 2006 | volume= 12 | issue= 12 | pages= 1431-48 | pmid=16611127 | doi=10.2174/138161206776389868 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16611127  }} </ref> Phenytoin inhibits [[sodium]] (Na) and [[calcium]] (Ca) channels which act as membrane stabilizers, as a result of which [[free radicals]] are released and cause endothelial damage, [[myocardial depression]], [[bradycardia]], and consequently [[fetal hypoxia]]. [[Phenytoin]] induces [[cytochrome P450]] activation which ends up within the release of [[teratogenic]] [[free radicals]], sourced via the metabolism of [[epoxides]], [[folate]], and [[vitamin K]] within the [[liver]].<ref name="pmid24323366">{{cite journal| author=Nilsson MF, Ritchie H, Webster WS| title=The effect on rat embryonic heart rate of Na+, K+, and Ca2+ channel blockers, and the human teratogen phenytoin, changes with gestational age. | journal=Birth Defects Res B Dev Reprod Toxicol | year= 2013 | volume= 98 | issue= 5 | pages= 416-27 | pmid=24323366 | doi=10.1002/bdrb.21084 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24323366  }} </ref><ref name="pmid11283972">{{cite journal| author=Azarbayjani F, Danielsson BR| title=Phenytoin-induced cleft palate: evidence for embryonic cardiac bradyarrhythmia due to inhibition of delayed rectifier K+ channels resulting in hypoxia-reoxygenation damage. | journal=Teratology | year= 2001 | volume= 63 | issue= 3 | pages= 152-60 | pmid=11283972 | doi=10.1002/tera.1026 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11283972 }} </ref>





Revision as of 08:13, 10 May 2021

Overview

Fetal hydantoin syndrome (FHS), characterized by altered growth and development, has been well described in recent years in the fetus of epileptic mothers taking phenytoin or other hydantoin anticonvulsants during the gestational period.[1]


Historical Perspective

Fetal hydanoin syndrom was first discovered by Meadow et al. in 1968. Manson and Frederic clarified the teratogenic effects of hydantoin in their epidemiological studies in 1973.[2]

Classification

There is no established system for the classification of Fetal hydantoin syndrome.

Pathophysiology

It is understood that fetal hydantoin syndromes is the result of infants born to mothers with seizure disorders treated with anticonvulsant medications during pregnancy are at an increased risk for teratogenic effects.[3]Although the exact pathogenesis of phenytoin (PTN) embryo toxicity is not clear, some possible mechanisms have been proposed.[4] Phenytoin inhibits sodium (Na) and calcium (Ca) channels which act as membrane stabilizers, as a result of which free radicals are released and cause endothelial damage, myocardial depression, bradycardia, and consequently fetal hypoxia. Phenytoin induces cytochrome P450 activation which ends up within the release of teratogenic free radicals, sourced via the metabolism of epoxides, folate, and vitamin K within the liver.[5][6]




Epidemiology and Demographics

The risk of neurological impairment estimated to be 1% to 11% is 2 to 3 times higher than in the general population. The risk of oral clefts and cardiac anomalies is 5 times than others in hydantoin exposed infants. Less frequently observed abnormalities include microcephaly, ocular defects, hypospadias, umbilical and inguinal hernias.[3]

Diagnosis

Diagnostic Study of Choice

There are no established criteria for the diagnosis of fetal hydantoin syndrome.

History and Symptoms

The patient with fetal hydantoin syndrome has a positive history of exposure to phenytoin during pregnancy. Common symptoms of fetal hydantoin syndrome include microcephaly, mental retardation, limb defects including hypoplastic nails and distal phalanges, heart defects.

Physical Examination

Common physical examination findings of fetal hydantoin syndrome include

  • microcephaly, distinctive facial and limb anomalies, ocular defects, growth deficiency, congenital heart defects, cardiac rhythm disturbances, and variable systemic abnormalities involving the nervous, renal, and gastrointestinal systems.
  • Congenital heart diseases associated with fetal hydantoin syndrome include pulmonary or aortic valvular stenosis, coarctation of aorta, patent ductus arteriosus, and ventricular septal defects.[7]

Laboratory Findings

  1. Jimenez JF, Seibert RW, Char F, Brown RE, Seibert JJ (1981). "Melanotic neuroectodermal tumor of infancy and fetal hydantoin syndrome". Am J Pediatr Hematol Oncol. 3 (1): 9–15. PMID 6263127.
  2. Ozkinay F, Yenigün A, Kantar M, Ozkinay C, Avanoğlu A, Ulman I (1998). "Two siblings with fetal hydantoin syndrome". Turk J Pediatr. 40 (2): 273–8. PMID 9677735.
  3. 3.0 3.1 Singh R, Kumar N, Arora S, Bhandari R, Jain A (2012). "Fetal hydantoin syndrome and its anaesthetic implications: a case report". Case Rep Anesthesiol. 2012: 370412. doi:10.1155/2012/370412. PMC 3469078. PMID 23082254.
  4. Webster WS, Howe AM, Abela D, Oakes DJ (2006). "The relationship between cleft lip, maxillary hypoplasia, hypoxia and phenytoin". Curr Pharm Des. 12 (12): 1431–48. doi:10.2174/138161206776389868. PMID 16611127.
  5. Nilsson MF, Ritchie H, Webster WS (2013). "The effect on rat embryonic heart rate of Na+, K+, and Ca2+ channel blockers, and the human teratogen phenytoin, changes with gestational age". Birth Defects Res B Dev Reprod Toxicol. 98 (5): 416–27. doi:10.1002/bdrb.21084. PMID 24323366.
  6. Azarbayjani F, Danielsson BR (2001). "Phenytoin-induced cleft palate: evidence for embryonic cardiac bradyarrhythmia due to inhibition of delayed rectifier K+ channels resulting in hypoxia-reoxygenation damage". Teratology. 63 (3): 152–60. doi:10.1002/tera.1026. PMID 11283972.
  7. Hegde A, Kaur A, Sood A, Dhanorkar M, Varma HT, Singh G; et al. (2017). "Fetal Hydantoin Syndrome". J Pediatr. 188: 304. doi:10.1016/j.jpeds.2017.05.018. PMID 28578158.